Theravance Biopharma, Inc. (TBPH)

Market Cap	443.12M
Revenue (ttm)	57.42M
Net Income (ttm)	-55.19M
Shares Out	48.16M
EPS (ttm)	-1.00
PE Ratio	n/a
Forward PE	7.18
Dividend	n/a
Ex-Dividend Date	n/a

Volume	351,232
Open	9.51
Previous Close	9.52
Day's Range	9.15 - 9.52
52-Week Range	8.21 - 11.98
Beta	0.35
Analysts	Strong Buy
Price Target	20.50 (+122.83%)
Earnings Date	May 6, 2024

About TBPH

Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States and Europe. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company's product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma. It has licensing and collabora...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Rick E. Winningham M.B.A.
• Employees: 99
• Stock Exchange: NASDAQ
• Ticker Symbol: TBPH

Analyst Forecast

According to 2 analysts, the average rating for TBPH stock is "Strong Buy." The 12-month stock price forecast is $20.5, which is an increase of 122.83% from the latest price.

Price Target

$20.5

(122.83% upside)

Analyst Consensus: Strong Buy